FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.

ABSTRACT:

Background

Two US Food and Drug Administration (FDA)-authorized coronavirus disease 2019 (COVID-19) mRNA vaccines, BNT162b2 (Pfizer/BioNTech) and mRNA-1273 (Moderna), have demonstrated high efficacy in large phase 3 randomized clinical trials. It is important to assess their effectiveness in a real-world setting.

Methods

This is a retrospective analysis of 136,532 individuals in the Mayo Clinic health system (Arizona, Florida, Iowa, Minnesota, and Wisconsin) with PCR testing data between December 1, 2020 and April 20, 2021. We compared clinical outcomes for a vaccinated cohort of 68,266 individuals who received at least one dose of either vaccine (n_BNT162b2 = 51,795; n_mRNA-1273 = 16,471) and an unvaccinated control cohort of 68,266 individuals propensit

SUBMITTER: Pawlowski C 

PROVIDER: S-EPMC8238652 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature